Commission Delegated Regulation (EU) 2025/1222 of 2 April 2025 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council as regards the harmonised classification and labelling of certain substances

ANNEX
ANNEX
Part 3, Table 3, of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:
(1)
the following entries are inserted following the consecutive order of the index numbers corresponding to each entry:
Index No
Chemical Name
EC No
CAS No
Classification
Labelling
Specific Conc. Limits, M-factors and ATEs
Notes
Hazard Class and Category Code(s)
Hazard statement Code(s)
Pictogram, Signal Word Code(s)
Hazard statement Code(s)
Suppl. Hazard statement Code(s)
‘607-776-00-5
2-ethylhexanoic acid, monoester with propane-1,2-diol
285-503-5
85114-00-7
Repr. 1B
H360D
GHS08
Dgr
H360D’
‘612-300-00-4
N -1-naphthylaniline;
N -phenylnaphthalen-1-amine
201-983-0
90-30-2
Acute Tox. 4
STOT RE 2
Skin Sens. 1
H302
H373 (blood system, liver)
H317
GHS07
GHS08
Wng
H302
H373 (blood system, liver)
H317
oral: ATE = 1 200  mg/kg bw’
‘026-005-00-8
tetrairon tris(pyrophosphate); ferric pyrophosphate
233-190-0
10058-44-3
Eye Irrit. 2
H319
GHS07
Wng
H319’
‘604-103-00-7
α,α’-propylenedinitrilodi- o -cresol
202-374-2
94-91-7
Repr. 1B
H360FD
GHS08
Dgr
H360FD’
‘008-004-00-4
ozone
233-069-2
10028-15-6
Ox. Gas 1
Carc. 2
Muta. 2
Acute Tox. 1
STOT SE 1
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H270
H351
H341
H330
H370 (nervous system, respiratory system, cardiovascular system)
H372 (nervous system, respiratory system)
H400
H410
GHS03
GHS08
GHS06
GHS09
Dgr
H270
H351
H341
H330
H370 (nervous system, respiratory system, cardiovascular system)
H372 (nervous system, respiratory system)
H410
inhalation: ATE = 10 ppmV
STOT SE 1; H370: C ≥ 0,002 %
STOT SE 2; H371: 0,0005 % ≤ C < 0,002 %
STOT RE 1; H372: C ≥ 0,05 %
STOT RE 2; H373: 0,01 % ≤ C < 0,05 %
M = 100
M = 1’
‘007-031-00-9
dinitrogen oxide
233-032-0
10024-97-2
Repr. 1B
STOT SE 3
STOT RE 1
Ozone 1
H360Df
H336
H372 (nervous
system)
H420
GHS08
GHS07
Dgr
H360Df
H336
H372 (nervous
system)
H420’
‘056-006-00-9
barium chromate
233-660-5
10294-40-3
Carc. 1B
H350
GHS08
Dgr
H350’
‘650-060-00-2
Chrysanthemum cinerariaefolium , extract from open and mature flowers of Tanacetum cinerariifolium obtained with supercritical CO 2
289-699-3
89997-63-7
Acute Tox. 4
Acute Tox. 4
STOT SE 1
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H332
H302
H370 (nervous system)
H373 (respiratory tract, inhalation)
H317
H400
H410
GHS07
GHS08
Dgr
H332
H302
H370 (nervous system)
H373 (respiratory tract, inhalation)
H317
H410
inhalation: ATE = 2,6 mg/L (dusts or mists)
oral: ATE = 730 mg/kg bw
M = 1 000
M = 100’
‘650-059-00-7
Chrysanthemum cinerariaefolium , extract from open and mature flowers of Tanacetum cinerariifolium obtained with hydrocarbon solvents
289-699-3
89997-63-7
Acute Tox. 4
Acute Tox. 4
STOT SE 1
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H332
H302
H370 (nervous system)
H373 (respiratory tract, inhalation)
H317
H400
H410
GHS07
GHS08
Dgr
H332
H302
H370 (nervous system)
H373 (respiratory tract, inhalation)
H317
H410
inhalation: ATE = 2,6 mg/L (dusts or mists)
oral: ATE = 730 mg/kg bw
M = 1 000
M = 100’
‘607-777-00-0
barium bis[2-chloro-5-[(2-hydroxy-1-naphthyl)azo]toluene-4-sulphonate]; C.I. Pigment Red 53:1
225-935-3
5160-02-1
Carc. 2
H351
GHS08
Wng
H351’
‘608-070-00-X
2-bromo-2-(bromomethyl)pentanedinitrile; [DBDCB]
252-681-0
35691-65-7
Acute Tox. 2
Acute Tox. 4
STOT RE 2
Eye Dam. 1
Skin Sens. 1A
Aquatic Chronic 2
H330
H302
H373 (thyroid, central nervous system)
H318
H317
H411
GHS06
GHS08
GHS05
GHS09
Dgr
H330
H302
H373 (thyroid, central nervous system)
H318
H317
H411
inhalation: ATE = 0,27 mg/L (dusts or mists)
oral: ATE = 500 mg/kg bw
Skin Sens. 1A; H317: C ≥ 0,001 %’
‘607-779-00-1
9-octadecenoic acid (Z)-, sulfonated, potassium salts [1]; Reaction products of fatty acids, C18 (unsaturated) alkyl with sulfur trioxide, potassium salts [2]; 9(or 10)-sulphooctadecanoic acid, potassium salt [3]
271-843-1 [1];
- [2];
267-966-5 [3]
68609-93-8 [1];
- [2];
67968-63-2 [3]
Repr. 1B
H360D
GHS08
Dgr
H360D’
‘613-352-00-0
bixlozone (ISO); 2-(2,4-dichlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one
—
81777-95-9
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
M = 1
M = 10’
‘603-248-00-3
2,3-epoxypropyl isopropyl ether
223-672-9
4016-14-2
Repr. 1B
H360F
GHS08
Dgr
H360F’
‘607-778-00-6
tetrahydrofurfuryl methacrylate
219-529-5
2455-24-5
Repr. 1B
Skin Sens. 1A
H360Df
H317
GHS08
GHS07
Dgr
H360Df
H317’
‘015-209-00-2
trimethyl phosphate
208-144-8
512-56-1
Carc. 1B
Muta. 1B
Repr. 1B
Acute Tox. 4
STOT RE 2
H350
H340
H360FD
H302
H373 (nervous system)
GHS08
GHS07
Dgr
H350
H340
H360FD
H302
H373 (nervous system)
oral: ATE = 1 300  mg/kg bw’
‘602-111-00-5
fluoroethylene
200-832-6
75-02-5
Carc. 1A
Muta. 2
H350
H341
GHS08
Dgr
H350
H341
D’
‘602-112-00-0
2-bromo-3,3,3-trifluoroprop-1-ene
—
1514-82-5
Repr. 1B
STOT SE 3
STOT SE 3
H360FD
H335
H336
GHS08
GHS07
Dgr
H360FD
H335
H336’
‘613-353-00-6
2-methyl-2 H -isothiazol-3-one hydrochloride; 2-methyl-2,3-dihydro-1,2-thiazol-3-one hydrochloride
247-499-3
26172-54-3
Acute Tox. 2
Acute Tox. 3
Acute Tox. 3
Skin Corr. 1
Eye Dam. 1
Skin Sens. 1A
Acute Aquatic 1
Acute Chronic 1
H330
H311
H301
H314
H318
H317
H400
H410
GHS06
GHS05
GHS09
Dgr
H330
H311
H301
H314
H317
H410
EUH071
inhalation: ATE = 0,15 mg/L (dusts or mists)
dermal: ATE = 320 mg/kg bw
oral: ATE = 180 mg/kg bw
Skin. Sens 1A; H317: C ≥ 0,0015 %
M = 10
M = 1’
‘603-249-00-9
2,3-epoxypropyl o-tolyl ether
218-645-3
2210-79-9
Skin Irrit. 2
Skin Sens. 1A
Muta. 2
Aquatic Chronic 2
H315
H317
H341
H411
GHS07
GHS08
GHS09
Wng
H315
H317
H341
H411
C’
‘607-780-00-7
methyl oct-2-ynoate
203-836-6
111-12-6
Skin Sens. 1A
H317
GHS07
Wng
H317’
‘612-301-00-X
dinotefuran (ISO); ( RS )-1-methyl-2-nitro-3-(tetrahydro-3-furylmethyl)guanidine
-
165252-70-0
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H302
H400
H410
GHS07
GHS09
Wng
H302
H410
oral: ATE = 2 000  mg/kg bw
M = 10
M = 10’
(2)
the entries corresponding to index numbers 015-012-00-1, 601-027-00-6, 602-025-00-8, 607-231-00-1, 613-044-00-6, 613-045-00-1, 615-008-00-5, 616-145-00-3, 616-211-00-1, 616-212-00-7 are replaced by the following entries respectively:
Index No
Chemical Name
EC No
CAS No
Hazard Class and Category Code(s)
Hazard statement Code(s)
Pictogram, Signal Word Code(s)
Hazard statement Code(s)
Suppl. Hazard statement Code(s)
Specific Conc. Limits, M-factors and ATEs
Notes
‘601-027-00-6
2-phenylpropene; α-methylstyrene
202-705-0
98-83-9
Flam. Liq. 3
Carc. 2
STOT SE 3
Eye Irrit. 2
Skin Sens. 1B
Aquatic Chronic 2
H226
H351
H335
H319
H317
H411
GHS02
GHS08
GHS07
GHS09
Wng
H226
H351
H335
H319
H317
H411
STOT SE 3; H335: C ≥ 25 %
D’
‘616-145-00-3
pethoxamid (ISO); 2-chloro- N -(2-ethoxyethyl)- N -(2-methyl-1-phenylprop-1-enyl)acetamide
-
106700-29-2
Acute Tox. 4
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H302
H317
H400
H410
GHS07
GHS09
Wng
H302
H317
H410
oral: ATE = 980 mg/kg bw
M = 100
M = 10’
‘015-012-00-1
tetraphosphorus trisulphide; phosphorus sesquisulphid
215-245-0
1314-85-8
Flam. Sol. 1
Self-heat. 1
Acute Tox. 4*
H228
H251
H302
GHS02
GHS07
Dgr
H228
H251
H302
T’
‘602-025-00-8
1,1-dichloroethylene; vinylidene chloride
200-864-0
75-35-4
Flam. Liq. 1
Carc. 1B
Muta. 2
Acute Tox. 1
Acute Tox. 3
STOT RE 1
Aquatic Chronic 3
H224
H350
H341
H330
H301
H372 (respiratory tract, kidney, liver)
H412
GHS02
GHS08
GHS06
Dgr
H224
H350
H341
H330
H301
H372 (respiratory tract, kidney, liver)
H412
inhalation: ATE = 0,5 mg/L (vapours)
oral: ATE = 300 mg/kg bw
D’
‘615-008-00-5
3-isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate; isophorone di-isocyanate
223-861-6
4098-71-9
Acute Tox. 1
Skin Corr. 1
Eye Dam. 1
Resp. Sens. 1
Skin Sens. 1A
Aquatic Chronic 2
H330
H314
H334
H317
H411
GHS06
GHS05
GHS08
GHS09
Dgr
H330
H314
H318
H334
H317
H411
EUH071
inhalation: ATE = 0,03 mg/L (dusts or mists)
Resp. Sens. 1; H334: C ≥ 0,5 % Skin Sens. 1A; H317: C ≥ 0,001 %
2’
‘613-045-00-1
folpet (ISO); N -(trichloromethylthio)phthalimide
205-088-6
133-07-3
Carc. 2
Acute Tox. 2
STOT RE 1
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H351
H330
H372 (respiratory tract)
H318
H317
H400
H410
GHS08
GHS06
GHS05
GHS09
Dgr
H351
H330
H372 (respiratory tract)
H318
H317
H410
EUH066
inhalation: ATE = 0,30 mg/L (dusts or mists)
STOT RE 1: C ≥ 5 %
STOT RE 2: 0,5 % ≤ C < 5 %
Skin Sens. 1A; H317: C ≥ 0,001 %
M = 10
M = 10’
‘613-044-00-6
captan (ISO); 1,2,3,6-tetrahydro- N -(trichloromethylthio)phthalimide
205-087-0
133-06-2
Carc. 2
Repr. 2
Acute Tox. 2
STOT RE 1
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H351
H361f
H330
H372
H318
H317
H400
H410
GHS08
GHS06
GHS05
GHS09
Dgr
H351
H361f
H330
H372
H318
H317
H410
inhalation: ATE
= 0,22 mg/L
(dusts or
mists)
Skin Sens. 1A; H317: C≥ 0,001 %
M = 10
M = 10’
‘607-231-00-1
clopyralid (ISO); 3,6-dichloropyridine-2-carboxylic acid
216-935-4
1702-17-6
Eye Dam. 1
Aquatic Chronic 1
H318
H410
GHS05
GHS09
Dgr
H318
H410
EUH066
M = 10’
‘616-211-00-1
proquinazid (ISO); 6-iodo-2-propoxy-3-propylquinazolin-4(3 H )-one
—
189278-12-4
Carc. 2
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H372 (thyroid,
liver)
H400
H410
GHS08
GHS09
Dgr
H351
H372 (thyroid,
liver)
H410
M = 1
M = 10’
‘616-212-00-7
3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate
259-627-5
55406-53-6
Acute Tox. 2
Acute Tox. 4
STOT RE 1
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H330
H302
H372 (larynx)
H318
H317
H400
H410
GHS06
GHS08
GHS05
GHS09
Dgr
H330
H302
H372 (larynx)
H318
H317
H410
inhalation: ATE
= 0,17 mg/L
(dusts or mists)
M = 10
M = 10’
Commission Delegated Regulation (EU) 2025/1222 of 2 April 2025 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council as regards the harmonised classification and labelling of certain substances

Schedules & Appendices

Cite this act
